| Denia International Drugs | |
| 48 Park Ave, Paterson, New Jersey 07501 | |
| (973) 345-4900 |
| Name | Denia International Drugs |
|---|---|
| Organization Name | Denia International Drugs Inc |
| Location | 48 Park Ave, Paterson, New Jersey 07501 |
| Type | Pharmacy |
| Phone | (973) 345-4900 |
| Participate in Medicare | Medicare enrolled and may accept medicare assignment. Please check with the supplier if they accept medicare-approved amount before you get your prescription drugs, equipment or supplies from this supplier. |
News Archive
Noninvasive device could benefit patients with kidney disease, congestive heart failure, or dehydration.
Using Vfend (voriconazole) for the treatment of nonneutropenic patients with candidemia, an often-fatal hospital-acquired bloodstream infection, is as effective as a regimen of two older antifungals and carries fewer serious side effects than that regimen.
Researchers at the Centre for Addiction and Mental Health (CAMH) led a study discovering a gene for a new form of intellectual disability, as well as how it likely affects cognitive development by disrupting neuron functioning.
Researchers have found that Zika virus can live in eyes and have identified genetic material from the virus in tears, according to a study from Washington University School of Medicine in St. Louis.
Fresenius Kabi Pharmaceuticals Holding, Inc., announced today that APP Pharmaceuticals will immediately begin marketing Oxaliplatin Injection (liquid) in the U.S. The U.S. Food and Drug Administration granted approval to market Oxaliplatin Injection in two dosage strengths to Fresenius Kabi Oncology Limited. APP Pharmaceuticals and Fresenius Kabi Oncology Limited are members of the Fresenius Kabi Group of companies. APP currently markets the lyophilized product, Oxaliplatin for Injection, 50 mg and 100 mg.
› Verified 3 days ago
| NPI Number | 1326181140 |
| Organization Name | DENIA INTERNATIONAL DRUGS, INC |
| Doing Business As | INTERNATIONAL DRUGS |
| Type | Pharmacy |
| Address | 48 Park Ave, Paterson, NJ 07501 |
| Phone Number | 973-345-4900 |
News Archive
Noninvasive device could benefit patients with kidney disease, congestive heart failure, or dehydration.
Using Vfend (voriconazole) for the treatment of nonneutropenic patients with candidemia, an often-fatal hospital-acquired bloodstream infection, is as effective as a regimen of two older antifungals and carries fewer serious side effects than that regimen.
Researchers at the Centre for Addiction and Mental Health (CAMH) led a study discovering a gene for a new form of intellectual disability, as well as how it likely affects cognitive development by disrupting neuron functioning.
Researchers have found that Zika virus can live in eyes and have identified genetic material from the virus in tears, according to a study from Washington University School of Medicine in St. Louis.
Fresenius Kabi Pharmaceuticals Holding, Inc., announced today that APP Pharmaceuticals will immediately begin marketing Oxaliplatin Injection (liquid) in the U.S. The U.S. Food and Drug Administration granted approval to market Oxaliplatin Injection in two dosage strengths to Fresenius Kabi Oncology Limited. APP Pharmaceuticals and Fresenius Kabi Oncology Limited are members of the Fresenius Kabi Group of companies. APP currently markets the lyophilized product, Oxaliplatin for Injection, 50 mg and 100 mg.
› Verified 3 days ago
News Archive
Noninvasive device could benefit patients with kidney disease, congestive heart failure, or dehydration.
Using Vfend (voriconazole) for the treatment of nonneutropenic patients with candidemia, an often-fatal hospital-acquired bloodstream infection, is as effective as a regimen of two older antifungals and carries fewer serious side effects than that regimen.
Researchers at the Centre for Addiction and Mental Health (CAMH) led a study discovering a gene for a new form of intellectual disability, as well as how it likely affects cognitive development by disrupting neuron functioning.
Researchers have found that Zika virus can live in eyes and have identified genetic material from the virus in tears, according to a study from Washington University School of Medicine in St. Louis.
Fresenius Kabi Pharmaceuticals Holding, Inc., announced today that APP Pharmaceuticals will immediately begin marketing Oxaliplatin Injection (liquid) in the U.S. The U.S. Food and Drug Administration granted approval to market Oxaliplatin Injection in two dosage strengths to Fresenius Kabi Oncology Limited. APP Pharmaceuticals and Fresenius Kabi Oncology Limited are members of the Fresenius Kabi Group of companies. APP currently markets the lyophilized product, Oxaliplatin for Injection, 50 mg and 100 mg.
› Verified 3 days ago
Paterson Drug Inc Type: Pharmacy Location: 430 Madison Ave, Paterson, New Jersey 07524 Phone: (973) 278-5808 | |
Pharmacy Plus & Surgical Supplies Type: Long Term Care Pharmacy Location: 900 Main St, Paterson, New Jersey 07503 Phone: (862) 257-9990 | |
Florida Drugs Type: Long Term Care Pharmacy Location: 507 Broadway, Paterson, New Jersey 07514 Phone: (973) 742-6313 | |
Walgreens #5005 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 639 E 18th St, Paterson, New Jersey 07501 Phone: (973) 925-8885 | |
Mainfair Pharmacy Type: Pharmacy Location: 87 Main St, Paterson, New Jersey 07505 Phone: (973) 279-5510 |